Plain-English translation of NCT05397639 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether masupirdine, a new medication, can help reduce agitation in people with Alzheimer's disease. Agitation—feelings of restlessness, irritability, or behavioral outbursts—is a common and difficult symptom for people with Alzheimer's. The study will compare the medication at two different doses against a placebo (a pill with no active ingredient) to see if it's safe and effective.
Many people with Alzheimer's experience agitation that can be distressing and hard to manage. Current treatment options are limited, so researchers are testing this medication to see if it offers a new way to help calm these symptoms and improve quality of life.
You likely qualify if…
You likely don't qualify if…
You would visit a research clinic about 4 weeks before starting the study for screening tests. If you qualify, you would be randomly assigned to take either a low dose of the medication, a high dose, or a placebo—once daily by mouth for 12 weeks (about 3 months). You would have regular visits to the clinic so the research team can monitor your symptoms, check how well the medication is working, and watch for any side effects.
AI-generated summary from trial data · Jun 10, 2026 · Not medical advice
United States